APA (7th ed.) Citation

Pujol, J., De Pas, T., Rittmeyer, A., Vallières, E., Kubisa, B., Levchenko, E., . . . Lehmann, F. F. (2016). Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. Journal of thoracic oncology, 11(12), 2208-2217. https://doi.org/10.1016/j.jtho.2016.08.120

Chicago Style (17th ed.) Citation

Pujol, Jean-Louis, et al. "Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study." Journal of Thoracic Oncology 11, no. 12 (2016): 2208-2217. https://doi.org/10.1016/j.jtho.2016.08.120.

MLA (9th ed.) Citation

Pujol, Jean-Louis, et al. "Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study." Journal of Thoracic Oncology, vol. 11, no. 12, 2016, pp. 2208-2217, https://doi.org/10.1016/j.jtho.2016.08.120.